C16 Globotriaosylceramide-d9 (d18:1/16:0-d9)
(Synonyms: C16 Ceramide Trihexoside (d18:1/16:0-d9), Gb3 (d18:1/16:0-d9), N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-ceramide Trihexoside) 目录号 : GC46980A neuropeptide with diverse biological activities
Cas No.:2738376-84-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C16 Globotriaosylceramide-d9 (d18:1/16:0-d9) is intended for use as an internal standard for the quantification of C16 globotriaosylceramide by GC- or LC-MS. C16 Globotriaosylceramide (d18:1/16:0) is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide .1 C16 Globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.2 It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder.3 Plasma levels of C16 globotriaosylceramide are increased in patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.4 [Matreya, LLC. Catalog No. 1551]
1.Lingwood, C.A., and Branch, D.R.The role of glycosphingolipids in HIV/AIDSDiscov. Med.11(59)303-313(2011) 2.Hoffmann, P., HÜlsewig, M., Duvar, S., et al.On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometryRapid Commun. Mass. Spectrom.24(15)2295-2304(2010) 3.Feldt-Rasmussen, U., Rasmussen, A.K., Mersebach, H., et al.Fabry disease: A new challenge in endocrinology and metabolism•Eur. J. Endocrinol.146(6)741-742(2002) 4.Hou, Y., Li, J., Xie, H., et al.Differential plasma lipids profiling and lipid signatures as biomarkers in the early diagnosis of ovarian carcinoma using UPLC-MSMetabolomics12(18)(2015)
| Cas No. | 2738376-84-4 | SDF | |
| 别名 | C16 Ceramide Trihexoside (d18:1/16:0-d9), Gb3 (d18:1/16:0-d9), N-Hexadecanoyl-d9 (13,13,14,14,15,15,16,16,16)-ceramide Trihexoside | ||
| Canonical SMILES | O[C@H]1[C@H](O[C@]2([H])O[C@H](CO)[C@H](O[C@]3([H])[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)[C@H](O)[C@H]2O)[C@@H](CO)O[C@@H](OC[C@H](NC(CCCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)[C@H](O)/C=C/CCCCCCCCCCCCC)[C@@H]1O | ||
| 分子式 | C52H88D9NO18 | 分子量 | 1033.4 |
| 溶解度 | 储存条件 | Store at -20°C; protect from light | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9677 mL | 4.8384 mL | 9.6768 mL |
| 5 mM | 0.1935 mL | 0.9677 mL | 1.9354 mL |
| 10 mM | 0.0968 mL | 0.4838 mL | 0.9677 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet